Table 1 Demographic and clinical features of patients from both the Israeli and the US cohorts upon presentation
Characteristic | All subjects (n = 87) | Israeli cohort (n = 39) | US cohort (n = 48) | P value* |
|---|---|---|---|---|
Demographics, mean (SD) or n (%) | ||||
Sex, male | 58 (66.7) | 22 (56.4) | 36 (75) | 0.11 |
Race, Caucasian | 58/78 (74.3) | 29/31 (93.5) | 29/47 (61.7) | 0.001 |
Age at symptom onset in years | 11.6 (2.6) | 12.3 (2.6) | 10.9 (2.5) | 0.01 |
Age at diagnosis in years | 13 (2.8) | 14.3 (2.7) | 11.9 (2.5) | < 0.001 |
FHx of HLA-B27-associated disease (FDR) | 7 (8) | 2 (5.1) | 5 (10.4) | 0.45 |
Clinical characteristics, n (%) | ||||
Back pain | 40 (46) | 23 (59) | 17 (35.4) | 0.033 |
Sacroiliac tenderness | 27 (31) | 19 (48.7) | 8 (16.7) | 0.002 |
Positive modified Schober test | 13/65 (20) | 7/17 (41.2) | 6 (21.5) | 0.029 |
Positive FABER test | 12/66 (18.2) | 6/18 (33.3) | 6 (12.5) | 0.07 |
Enthesitis | 22 (25.3) | 3 (7.7) | 19 (39.6) | 0.001 |
Peripheral arthritis | 61 (70.1) | 17 (43.6) | 44 (91.7) | < 0.001 |
Arthritis in a male over 6 years old | 58 (66.7) | 22 (56.4) | 36 (75) | 0.11 |
Acute symptomatic uveitis | 3 (3.4) | 0 (0) | 3 (6.2) | 0.25 |
HLA-B27 positivity | 40/70 (54.8) | 8/25 (32) | 32 (66.7) | 0.007 |
ANA- positive | 19/73 (26) | 10/28 (35.7) | 9/45 (20) | 0.17 |
CRP, elevated | 36/74 (48.6) | 17/30 (56.7) | 19/44 (43.2) | 0.34 |
ESR, elevated | 30/62 (48.4) | 9/17 (52.9) | 21/45 (46.7) | 0.78 |
MRI defined Sacroiliitis | 40/67 (59.7) | 29/30 (96.7) | 11/37 (29.7) | < 0.001 |
Treatment before or at time of diagnosis, n (%) | ||||
NSAIDs | 72 (82.8) | 27 (69.2) | 45 (93.7) | 0.004 |
DMARDs (sulfasalazine or methotrexate) | 12 (13.8) | 8 (20.5) | 4 (8.3) | 0.13 |
Biologics | 7 (8) | 3 (7.7) | 4 (8.3) | 1 |